Chemistry and Pharmacology of Drugs of Abuse Annual Symposium

 描述(由申请人提供)：物质使用障碍(SUD)是对全球公共健康的普遍威胁，是全球疾病负担中最大的25个风险因素之一。作为尚未解决的重大医学问题，肥胖症的性质在一定程度上反映了我们目前对肥胖症的发病机制和治疗的认识的空白。药物滥用对全球健康造成的无休止负担的一个决定性因素是，能够对抗肥皂症并帮助实现通常的主要肥胖症治疗目标--持久戒除--的安全、有效的药物疗法数量有限。研究人员之间强有力的跨学科交流对于提高目前对成瘾的神经生物学基础的理解、激发对与滥用相关的药物研发的兴趣以及产生更好、更有效的反滥用疗法至关重要。实现这些目标的一个关键方面是药物化学和药理学的整合，为新药物的设计、合成、优化和(临床前)分析提供信息，以了解它们的药理作用和治疗肥皂症的治疗潜力。需要在与SUD相关的药物化学方面取得重大进展，以产生抗滥用候选药物，并扩大我们的药理学知识，即SUD疗法如何改变大脑(DYS)功能和复杂的成瘾循环表型之间的关系，以引起有益的反应。应用于SUDS的药物化学的进展也应该使临床前SUD模型的评估具有更好的实用性和翻译可靠性，特别是关于实验系统，这将有助于扩大以实施为导向的研究，重点是与成瘾病因和病理学相关的大脑功能。新的药物化学方法将产生候选的SUD疗法和分子成像工具，也可以提供对SUD病因学的洞察。我们的目标是在马萨诸塞州波士顿的东北大学校园里组织和举办为期两天的年度“滥用药物的化学和药理学”研讨会。拟议的会议旨在作为对前一年药物滥用研究中与研究有关的最重要进展的跨学科展示。专题议程将强调药物化学的实验室发现，这些发现为成瘾的药理学和病理机制提供信息，并探索SUD药物疗法。鉴于波士顿地区是全球公认的首屈一指的生物技术中心和领先的生物医学研究中心，以及当地主要的研究密集型临床中心(如麦克莱恩医院/哈佛医学院)的参与，从基础研究人员到医疗保健提供者和公共卫生官员，这次有重点的会议应该会引起不同支持者的极大兴趣和积极参与。

 DESCRIPTION (provided by applicant): Substance-use disorders (SUDs) are pervasive threats to global public health and constitute one of the top 25 top risk factors in the worldwide burden of disease. The nature of SUDs as major unsolved medical problems reflects to some degree the gaps in our current knowledge about SUD disease mechanisms and treatment. A decisive contributor to the unremitting global-health burden of drug abuse is the limited number of safe, effective pharmacotherapeutics able to combat SUDs and help attain the usual primary SUD treatment goal, durable abstinence. Strong, interdisciplinary communication among researchers is critical to improving current understanding of the neurobiological basis of addiction, stimulating interest in abuse-related pharmaceutical R&D, and generating better, more effective anti-abuse therapies. A key aspect of achieving these goals is the integration of medicinal chemistry and pharmacology to inform the design, synthesis, optimization, and (pre)clinical profiling of new agents for their pharmacological effects and their therapeutic potential for treating SUDs. Significant advances are required in SUD-related medicinal chemistry to produce anti-abuse drug candidates and expand our pharmacological knowledge as to how SUD therapies alter the relationships between brain (dys)function and the complex addiction-cycle phenotypes to elicit a salutary response. Advances in medicinal chemistry as applied to SUDs should also empower evaluation of preclinical SUD models with improved utility and translational reliability, especially regarding experimental systems that would help expand implementation-oriented research focused on brain function related to addiction etiology and pathology. New medicinal chemistry approaches that would generate both candidate SUD therapies and molecular imaging tools could also provide insight into SUD etiology. We aim to organize and conduct an annual, two-day "Chemistry and Pharmacology of Drugs of Abuse" symposium on campus of Northeastern University in Boston, MA. The proposed meeting is intended to serve as an interdisciplinary exposition of the prior year's most important, research-related advances in drug-abuse research. The topical agendas will emphasize laboratory findings in medicinal chemistry that inform the pharmacology and pathological mechanisms underlying addiction and the search for SUD pharmacotherapies. This focused meeting should garner substantial interest from and active participation by diverse constituencies, from basic researchers to healthcare providers and public-health officials, given worldwide recognition of the Boston area as a premiere biotechnology hub and leading biomedical research center and the involvement of major local, research-intensive clinical centers (e.g., McLean Hospital/Harvard Medical School) in SUD research and treatment.